English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

3SBio in-licensed Pegsiticase Global Rights

Nov. 28, 2010

3SBio Inc. (“3SBio”), a leading China-based biotechnology company announced on November 29, 2010 that it has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.
Pegsiticase (Uricase-PEG 20) is being developed for the treatment of refractory gout and tumor lysis syndrome. Pegsiticase has received Orphan Drug designation from the FDA for refractory gout, tumor lysis syndrome and Lesch-Nyhan Syndrome.